Navigation Links
Cardiologists and heart surgeons meet for 'Controversies and Advances' conference
Date:9/26/2007

LOS ANGELES (September 25, 2007) Stem cell therapy for cardiac regeneration and the controversial issue of medicine and the media will be the focus of the keynote addresses at the seventh annual Controversies and Advances in the Treatment of Cardiovascular Disease conference. Conducted by Cedars-Sinai Medical Center at the Beverly Hills Hotel on Oct. 4 and 5, the conference is co-sponsored by the California Chapter of the American College of Cardiology, the California Chapter of the Society of Thoracic Surgeons, and Promedica International CME.

Professional differences of opinion often have stood between heart surgeons and cardiologists, and recent innovations in minimally invasive medical procedures have done nothing to reduce the friction. The ongoing debate as to whether it is better to replace and repair aortic and mitral valves surgically or to manage them medically is just one example. And when considering treatment options for Atrial Fibrillation, the choices are even more diverse should the physician opt for minimally invasive surgery, drugs or a catheter treatment" And then there is the highly controversial stent issue drug-eluting vs. bare metal which is better"

This major symposium one of the very few that brings together both cardiologists and heart surgeons will directly explore the controversies and latest medical and surgical advances in an open forum. Many subjects will be addressed in debate formats. Others will be lectures presented by highly respected leaders in their fields.

Lawrence K. Altman, M.D., author of the book Who Goes First" The Story of Self-Experimentation in Medicine and a member of the New York Times science news staff since 1969, will be one of two keynote speakers. Altman, senior medical correspondent at the Times, has published an average of 100 scientific stories a year and writes the column Doctors World. His remarks will focus on medicine and the media.

A clinical professor at New
'/>"/>

Contact: Sandy Van
sandy@prpacific.com
800-880-2397
Cedars-Sinai Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
2. UCSD team discovers specialized, rare heart stem cells in newborns
3. Implanted Devices Detect High-Risk Heart Failure Patients
4. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
5. Special Imaging Study Shows Failing Hearts Are Energy Starved
6. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
7. Single stem cells from bone heal a broken heart
8. Heart repair gets new muscle
9. Python a hearty eater
10. Columbia study shows widely used artery clearing device does not help patients during heart attack
11. Researchers reveal secret of key protein in brain and heart function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... detected from space for the first time using optical ... aboard Envisat. The ability to monitor Sargassum globally will ... the ocean and better predict climate change. Credit: ESA ... ships in its dense floating vegetation, has been detected ...
... are moving closer to understanding why the most lethal ... treatment in the past three decades. They have been ... a protozoan gene that contributes to such resistance. And ... constructed over a two-year period is believed to be ...
... postdoctoral fellow at the University of Oregon, has shown that ... soil bacteria needed to provide a natural fertilizer to crops. ... boost crop yields may instead be contributing to growth problems, ... years of research both in the test tube and, now, ...
Cached Biology News:Envisat captures first image of Sargassum from space 2Largest synthetic gene ever built offers insights into anti-malarial drug resistance 2Largest synthetic gene ever built offers insights into anti-malarial drug resistance 3Largest synthetic gene ever built offers insights into anti-malarial drug resistance 4Pesticides choke pathway for nature to produce nitrogen for crops 2Pesticides choke pathway for nature to produce nitrogen for crops 3
(Date:7/30/2015)... , July 30, 2015   GenoSpace , ... the interpretation and analysis of genomic and other ... has joined the company as Vice President ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners ... integrate, interpret, analyze and explore complex sets of ...
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)... , Inc. (NASDAQ: SNMX ), a leading company ... commercialize novel flavor ingredients for the food, beverage, and ... second quarter 2015. "Moving into the ... achieve our commercial and financial goals," stated John Poyhonen, ... our last quarterly earnings report, our two partners have ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against ... were $697 million compared to $701 million in the ... and changes in foreign currency exchange rates decreased sales ... , By business unit, organic sales growth was 6% ... Commercial. , Reported diluted EPS was $0.98 compared ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... sets the new global standard to eradicate ... in health care facilities, including MRSA and ... ... BioNeutral announces successful,testing of its Ygiene(TM) Hospital Grade antimicrobial against,antibiotic-resistant microorganisms ...
... Xceed Molecular, a pioneer in,the development of ... has selected the company,s Ziplex,System as a recipient ... Oscars of Invention by The Chicago Tribune, the ... mark of excellence known to industry,government, and academia ...
... SEATTLE and OSLO, Norway, Aug. 19 ... Affitech AS, a,Norwegian human antibody therapeutics company, ... agreement for the discovery and development of ... or mannan-binding,lectin-associated serine protease-2, mediates activation of ...
Cached Biology Technology:BioNeutral's Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World 2BioNeutral's Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World 3BioNeutral's Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World 4Xceed Ziplex(R) System for Automated Gene-Expression Analysis Wins 2008 R&D 100 Award 2Affitech and Omeros Enter Into Antibody Discovery and Development Agreement 2Affitech and Omeros Enter Into Antibody Discovery and Development Agreement 3
... does for enzyme-/substrate-based blotting what intensifying screens do ... up to 10-fold (or one order of magnitude) ... Signal Enhancer membrane treatment is a simple, 15-minute ... current Western blotting protocol. The result is an ...
...
... Expression is a revolutionary new ... analysis. Utilising a novel interface, Expression ... information incredibly simple. Expression uses the ... new standards in the way sequences ...
... Solution is a comprehensive suite of ... specifically designed to reliably extract biological ... genomic studies containing thousands of samples, ... efficient and will analyze large data ...
Biology Products: